Bowel cancer drug that shrunk 60% of tumours in incredibly exciting trial is hailed a game-changer [Video]

A COMBINATION of two immunotherapy drugs could be used to treat the most common form of bowel cancer, scientists say.

“Incredibly exciting” trials showed tumours had shrunk or remained stable in three out of five patients.

Botensilimab and balstilimab could “offer new hope” for those diagnosed with a type of cancer that has previously not responded to immunotherapy, researchers from Anglia Ruskin University said.

Both drugs work by triggering the body’s immune system to attack cancer cells.

Describing the treatment as “potentially game changing”, the team said it hopes authorities in the UK will be “able to move quickly” in approving its use.

The researchers followed 101 people in the US who were diagnosed with microsatellite stable metastatic colorectal cancer (MSS mCRC) – the most common type of bowel cancer.

After six months, tumours were shown to shrink or remain stable …